Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications

Background—Serotonergic medications with various mechanisms of action are used to treat psychiatric disorders and are being investigated as treatments for drug dependence. The occurrence of fenfluramine-associated valvular heart disease (VHD) has raised concerns that other serotonergic medications might also increase the risk of developing VHD. We hypothesized that fenfluramine or its metabolite norfenfluramine and other medications known to produce VHD have preferentially high affinities for a particular serotonin receptor subtype capable of stimulating mitogenesis. Methods and Results—Medications known or suspected to cause VHD (positive controls) and medications not associated with VHD (negative controls) were screened for activity at 11 cloned serotonin receptor subtypes by use of ligand-binding methods and functional assays. The positive control drugs were (±)-fenfluramine; (+)-fenfluramine; (−)-fenfluramine; its metabolites (±)-norfenfluramine, (+)-norfenfluramine, and (−)-norfenfluramine; ergotamine; and methysergide and its metabolite methylergonovine. The negative control drugs were phentermine, fluoxetine, its metabolite norfluoxetine, and trazodone and its active metabolite m-chlorophenylpiperazine. (±)-, (+)-, and (−)-Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin 5-HT2B receptor and were partial to full agonists at the 5-HT2B receptor. Conclusions—Our data imply that activation of 5-HT2B receptors is necessary to produce VHD and that serotonergic medications that do not activate 5-HT2B receptors are unlikely to produce VHD. We suggest that all clinically available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at 5-HT2B receptors.

[1]  V. Rigolin,et al.  Appetite suppressants and valvular heart disease. , 2002, Current opinion in cardiology.

[2]  T. Ryan,et al.  Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. , 2000, Circulation.

[3]  R. Rothman,et al.  Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications , 2000, Synapse.

[4]  R. Rothman,et al.  Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. , 2000, The American journal of cardiology.

[5]  B. Roth,et al.  2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. , 2000, Journal of medicinal chemistry.

[6]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.

[7]  T. Najarian,et al.  Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. , 1999, Circulation.

[8]  R. Porter,et al.  Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.

[9]  PJ Wellman,et al.  Synergistic interactions between Fenfluramine and Phentermine , 1999, International Journal of Obesity.

[10]  A. Fishman Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.

[11]  S. Erban,et al.  Risk for Valvular Heart Disease among Users of Fenfluramine and Dexfenfluramine Who Underwent Echocardiography before Use of Medication , 1998, Annals of Internal Medicine.

[12]  B. Roth,et al.  5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. , 1998, Pharmacology & therapeutics.

[13]  N. Weissman,et al.  An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. , 1998, The New England journal of medicine.

[14]  J. Vessey,et al.  The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. , 1998, The New England journal of medicine.

[15]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[16]  M. Lopez-Ilasaca Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. , 1998, Biochemical pharmacology.

[17]  J. Leysen,et al.  Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5‐HT1B and 5‐HT1D receptors expressed in various mammalian cell lines , 1998, British journal of pharmacology.

[18]  K. Otani,et al.  Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients , 1998, European Journal of Clinical Pharmacology.

[19]  B. Roth,et al.  Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. , 1997, Molecular pharmacology.

[20]  B. Roth,et al.  High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. , 1997, The Journal of pharmacology and experimental therapeutics.

[21]  B. Corya,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[22]  J. Van Dorpe,et al.  Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. , 1996, The Journal of heart valve disease.

[23]  J M Feldman,et al.  Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. , 1995, Circulation.

[24]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[25]  M. Baumann,et al.  Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats , 1993, Neuropharmacology.

[26]  P. Celada,et al.  Monoamine Oxidase Inhibitors Phenelzine and Brofaromine Increase Plasma Serotonin and Decrease 5‐Hydroxyindoleacetic Acid in Patients with Major Depression: Relationship to Clinical Improvement , 1992, Journal of clinical psychopharmacology.

[27]  J. Pouysségur,et al.  Serotonin stimulates DNA synthesis in fibroblasts acting through 5–HT1B receptors coupled to a Gi-protein , 1988, Nature.

[28]  P. Lecompte,et al.  Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. , 1974, American heart journal.

[29]  R. Kunkel,et al.  Complications of methysergide therapy: retroperitoneal fibrosis, mitral regurgitation, edema, and hemolytic anemia. , 1970, JAMA.